As of June 30, 2025, Beckley Psytech Limited has reported its unaudited interim condensed consolidated financial statements, showing changes in various financial metrics compared to the same period in 2024.
In terms of operating expenses, there was an increase in general and administrative expenses from £4,182,000 in 2024 to £5,219,000 in 2025. Research and development expenses remained relatively stable at £11,988,000 in 2024 compared to £11,406,000 in 2025.
The loss on contingent consideration, however, significantly increased from £3,105,000 in 2024 to £14,121,000 in 2025, contributing to an overall increase in operating loss from £19,275,000 in 2024 to £30,746,000 in 2025.
Interest income decreased from £550,000 in 2024 to £76,000 in 2025, while interest expenses amounted to £84,000 in 2025. The gain on revaluation of warrants also declined from £7,485,000 in 2024 to a loss of £6,765,000 in 2025.
The loss before income taxes increased from £11,240,000 in 2024 to £23,989,000 in 2025, and the income tax benefit decreased slightly from £3,762,000 in 2024 to £3,896,000 in 2025.
The total comprehensive loss for the period surged from £7,494,000 in 2024 to £20,260,000 in 2025.
Looking at the statement of financial position, the total assets decreased from £76,223,000 in 2024 to £62,232,000 in 2025. Non-current assets slightly increased from £50,472,000 in 2024 to £50,840,000 in 2025, while current assets decreased significantly from £25,751,000 in 2024 to £11,392,000 in 2025.
In terms of liabilities, total liabilities increased from £17,190,000 in 2024 to £23,131,000 in 2025. Current liabilities surged from £6,860,000 in 2024 to £16,840,000 in 2025, and non-current liabilities decreased from £10,330,000 in 2024 to £6,291,000 in 2025.
Net assets decreased from £59,033,000 in 2024 to £39,101,000 in 2025, with the accumulated deficit increasing from £68,226,000 in 2024 to £87,991,000 in 2025.
The cash and cash equivalents at the end of the period decreased significantly from £9,869,000 in 2024 to £1,622,000 in 2025, with a net cash used in operating activities of £26,894,000 in 2024 compared to £3,287,000 in 2025.
These unaudited interim condensed consolidated financial statements highlight the changes in key financial metrics for Beckley Psytech Limited, reflecting both positive and negative movements in various aspects of the company's financial performance. The market has reacted to these announcements by moving the company's shares -2.33% to a price of $5.45. If you want to know more, read the company's complete 8-K report here.
